FDA approves Verona drug for COPD


United States

The US Food and Drug Administration has approved a new drug for chronic obstructive pulmonary disease, the third leading cause of death worldwide. Ohtuvayre (ensifentrine), developed by Verona Pharma Plc, is an inhaled therapy for the maintenance treatment of COPD, a disease that is mainly caused by tobacco smoking. It was authorised by the FDA on 26 June.